ImpediMed Touts Strong Q4 Sales and Economic Impact

Impedimed Limited (AU:IPD) has released an update.

ImpediMed Limited reports a robust fourth quarter with a 168% increase in leads pipeline and sales of 38 SOZO units, of which 23 were in the US, demonstrating strong market adoption. The company recorded unaudited revenue of A$2.9 million and an end-of-quarter cash balance of A$24.6 million, while forecasting a 10% reduction in FY25 operating cash expenditure. A return on investment of 712% was highlighted from the New South Wales Health Department’s Lymphoedema Prevention Program, underscoring the economic value of early detection.

For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.